PURPOSE In recent years, the treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) have expanded significantly. In addition to androgen deprivation therapy, the systemic treatments now include docetaxel, abiraterone, enzalutamide, and apalutamide. Radiation to the primary is also an option for select low-volume patients. METHODS We conducted a review of the pivotal trials that have changed the practice of mHSPC. RESULTS We describe an overview of the trials that investigated docetaxel (CHAARTED and STAMPEDE-Docetaxel), abiraterone (LATTITUDE and STAMPEDE-Abiraterone), enzalutamide (ARCHES, ENZAMET), apalutamide (TITAN), and radiation to the primary (STAMPEDE-Radiation). DISCUSSION The treatment of mHSPC is a complex topic, and treatment choice should be individualized. Patient preferences, cost, volume of disease, and side effect profiles are important in determining which option is the best for an individual patient.

中文翻译：

---

转移性激素敏感性前列腺癌：当前治疗前景的回顾。

目的近年来，转移性激素敏感性前列腺癌（mHSPC）的治疗选择已大大扩展。除雄激素剥夺疗法外，全身治疗现在包括多西他赛，阿比特龙，恩杂鲁胺和阿帕鲁胺。对于某些小剂量患者，也可以选择向原发灶放射。方法我们对改变mHSPC实践的关键试验进行了回顾。结果我们描述了研究多西他赛（查特和STAMPEDE-多西他赛），阿比特龙（立特和STAMPEDE-阿比特龙），恩杂鲁胺（ARCHES，ENZAMET），阿帕鲁胺（TITAN）和对原发辐射（STAMPEDE-辐射）的试验概述。 。讨论mHSPC的治疗是一个复杂的话题，治疗选择应个体化。患者的喜好，费用，疾病数量，